SG10201401310VA - Method for treating immune disorders - Google Patents
Method for treating immune disordersInfo
- Publication number
- SG10201401310VA SG10201401310VA SG10201401310VA SG10201401310VA SG10201401310VA SG 10201401310V A SG10201401310V A SG 10201401310VA SG 10201401310V A SG10201401310V A SG 10201401310VA SG 10201401310V A SG10201401310V A SG 10201401310VA SG 10201401310V A SG10201401310V A SG 10201401310VA
- Authority
- SG
- Singapore
- Prior art keywords
- immune disorders
- treating immune
- treating
- disorders
- immune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16749709P | 2009-04-07 | 2009-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201401310VA true SG10201401310VA (en) | 2014-06-27 |
Family
ID=42935583
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011073061A SG175106A1 (en) | 2009-04-07 | 2010-04-07 | Method for treating immune disorders |
SG10201401310VA SG10201401310VA (en) | 2009-04-07 | 2010-04-07 | Method for treating immune disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011073061A SG175106A1 (en) | 2009-04-07 | 2010-04-07 | Method for treating immune disorders |
Country Status (11)
Country | Link |
---|---|
US (1) | US20120114555A1 (en) |
EP (1) | EP2416802A4 (en) |
JP (2) | JP5877784B2 (en) |
KR (1) | KR20120013351A (en) |
CN (1) | CN102802667B (en) |
AU (1) | AU2010234218C1 (en) |
CA (1) | CA2757933A1 (en) |
MX (1) | MX339022B (en) |
MY (1) | MY183617A (en) |
SG (2) | SG175106A1 (en) |
WO (1) | WO2010115238A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY183617A (en) * | 2009-04-07 | 2021-03-03 | Immune System Therapeutics Ltd | Method for treating immune disorders |
JP7229768B2 (en) * | 2015-04-23 | 2023-02-28 | ヒーマロジックス プロプライエタリー リミテッド | Kappa myeloma antigen chimeric antigen receptor and uses thereof |
AU2019225446B2 (en) * | 2018-02-20 | 2021-01-07 | Haemalogix Pty Ltd | Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders |
SG11202105877YA (en) * | 2018-12-03 | 2021-07-29 | Haemalogix Pty Ltd | Method of treatment |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5605398A (en) * | 1996-12-11 | 1998-07-03 | University Of Florida | Novel methods and compositions for treatment of autoimmune diseases |
AUPR617901A0 (en) * | 2001-07-06 | 2001-08-02 | Pacmab Pty Ltd | Method for treating multiple myeloma |
DK1720569T3 (en) * | 2004-02-27 | 2015-02-02 | Immune System Therapeutics Ltd | Targets for B-cell disorders |
WO2005103717A1 (en) * | 2004-04-21 | 2005-11-03 | Fornix Biosciences N.V. | Measuring free light chains of immunoglobulin |
AU2006292132A1 (en) * | 2005-09-19 | 2007-03-29 | Palingen, Inc. | Treatment of B cell diseases using anti-germline antibody binding agents |
MY183617A (en) * | 2009-04-07 | 2021-03-03 | Immune System Therapeutics Ltd | Method for treating immune disorders |
-
2010
- 2010-04-07 MY MYPI2011004795A patent/MY183617A/en unknown
- 2010-04-07 US US13/263,043 patent/US20120114555A1/en not_active Abandoned
- 2010-04-07 MX MX2011010624A patent/MX339022B/en active IP Right Grant
- 2010-04-07 WO PCT/AU2010/000394 patent/WO2010115238A1/en active Application Filing
- 2010-04-07 CN CN201080025215.9A patent/CN102802667B/en not_active Expired - Fee Related
- 2010-04-07 KR KR1020117025571A patent/KR20120013351A/en not_active Application Discontinuation
- 2010-04-07 SG SG2011073061A patent/SG175106A1/en unknown
- 2010-04-07 JP JP2012503833A patent/JP5877784B2/en not_active Expired - Fee Related
- 2010-04-07 SG SG10201401310VA patent/SG10201401310VA/en unknown
- 2010-04-07 CA CA2757933A patent/CA2757933A1/en not_active Abandoned
- 2010-04-07 AU AU2010234218A patent/AU2010234218C1/en not_active Ceased
- 2010-04-07 EP EP10761124.6A patent/EP2416802A4/en not_active Withdrawn
-
2015
- 2015-07-02 JP JP2015133839A patent/JP2015193637A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN102802667B (en) | 2016-08-17 |
EP2416802A4 (en) | 2013-05-15 |
JP2015193637A (en) | 2015-11-05 |
AU2010234218C1 (en) | 2016-01-14 |
KR20120013351A (en) | 2012-02-14 |
SG175106A1 (en) | 2011-11-28 |
JP5877784B2 (en) | 2016-03-08 |
EP2416802A1 (en) | 2012-02-15 |
MX2011010624A (en) | 2012-02-21 |
AU2010234218B2 (en) | 2015-10-08 |
US20120114555A1 (en) | 2012-05-10 |
AU2010234218A1 (en) | 2011-10-27 |
CA2757933A1 (en) | 2010-10-14 |
MY183617A (en) | 2021-03-03 |
CN102802667A (en) | 2012-11-28 |
JP2012522811A (en) | 2012-09-27 |
MX339022B (en) | 2016-05-05 |
WO2010115238A1 (en) | 2010-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201202299B (en) | Method for decreasing immunigenicity | |
WO2010144865A9 (en) | Methods for treating gastrointestinal disorders | |
ZA201401438B (en) | Methods for treating cardiovascular disorders | |
GB0911099D0 (en) | Processing method | |
EP2531625A4 (en) | Method for treating tailings | |
PL2526141T3 (en) | Method for surface treatment | |
EP2582374A4 (en) | Methods for treating neurological conditions | |
EP2485727A4 (en) | Pyrrolopyrazoles for treating cns disorders | |
ZA201208219B (en) | Method for treating wasterwater | |
IL217492A0 (en) | Treatment method | |
EP2405929A4 (en) | Treatment methods for autoimmune disorders | |
EP2378836A4 (en) | Inductive heating apparatus | |
IL220594A0 (en) | Treatment method | |
IL218633A0 (en) | Methods for treating psoriasis | |
EP2453896A4 (en) | Methods for treating schizophrenia | |
PT2393758E (en) | Method for treating wastewaters | |
ZA201200124B (en) | Method of treating age related disorders | |
SG10201401310VA (en) | Method for treating immune disorders | |
EP2723348A4 (en) | Method for treating obesity | |
PL2512267T3 (en) | Coffee treatment method | |
GB201108797D0 (en) | Surface treatment method | |
HK1134746A2 (en) | Method for treating boiler surface | |
IL205807A0 (en) | Method for object recognition | |
PL2292701T5 (en) | Method for improving opacity | |
GB201105523D0 (en) | Treatment method |